<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304278</url>
  </required_header>
  <id_info>
    <org_study_id>RAO-OSI-3601S</org_study_id>
    <secondary_id>Genentech, Inc.</secondary_id>
    <nct_id>NCT00304278</nct_id>
  </id_info>
  <brief_title>Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)</brief_title>
  <official_title>Phase II Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Illinois University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of treatment with
      Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with
      Head and Neck cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Head and neck malignancies represent a group of epidermoid tumors that arise from the
      epithelial lining of the mouth, pharynx, and larynx. Three modalities of therapy have
      established roles in the treatment of carcinoma of the head and neck: chemotherapy, radiation
      therapy (XRT), and surgery. The choice of modality depends upon many factors such as the site
      and extent of the primary lesion, the likelihood of complete surgical resection, the presence
      of lymph node metastases, etc. Traditionally, smaller lesions (stage T1-T2) are effectively
      treated either, by surgical excision or irradiation whereas more advanced disease (stage
      III-IV) is treated with combined surgery and XRT. The subsequent morbidity related to
      extensive surgery is a major problem among survivors. Clearly, there is a need to develop
      therapeutic strategies for patients with advanced head and neck cancer with more effective
      approaches employing non-surgical modalities.

      Our hypothesis is that head and neck cancers are resistant to apoptosis from DNA damage
      induced by radiation and chemotherapy. This resistance is mediated by EGFR overexpression
      which results in downstream activation of cell survival signals, such as AKT, and may be
      overcome when Erlotinib (Tarceva) is co-administered with RADiation and cisPLATin
      (intraarterial chemotherapy).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete and Partial Response Using RECIST Criteria</measure>
    <time_frame>17 weeks</time_frame>
    <description>Complete and Partial Response as defined by RECIST 1.0. Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Post Treatment</measure>
    <time_frame>22 months</time_frame>
    <description>Overall Survival with a minimum follow up of 1year. Relapse/Persistent Disease Rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>RADPLAT and Tarceva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive RADPLAT and Tarceva:
Drug: Erlotinib (Tarceva)
150 mg daily X 7 weeks
Other Names:
Tarceva
Drug: Intra-arterial Cisplatin (PLAT)
1 dose (150 mg/sq) per week X 4 weeks
Other Names:
Cisplatin
Radiation: Radiation Therapy (RAD)
5 days per week X 7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib (Tarceva)</intervention_name>
    <description>150 mg daily X 7 weeks</description>
    <arm_group_label>RADPLAT and Tarceva</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-arterial Cisplatin (PLAT)</intervention_name>
    <description>1 dose (150 mg/sq) per week X 4 weeks</description>
    <arm_group_label>RADPLAT and Tarceva</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy (RAD)</intervention_name>
    <description>5 days per week X 7 weeks</description>
    <arm_group_label>RADPLAT and Tarceva</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed Stage III-IV disease
             comprised of T3 or T4 N0-2 lesions of the oral cavity, oropharynx, hypopharynx, and
             larynx.

          -  No previous radiation therapy or chemotherapy.

          -  No evidence of distant metastatic disease.

          -  Age &gt; 18.

          -  Karnofsky performance status of &gt; 60 (ECOG 2).

          -  ANC &gt; 1000, platelets &gt; 100,000, calculated or 24-hour creatinine clearance &gt; 60.

          -  Study-specific informed consent form.

          -  Protocol treatment must begin &lt; 8 weeks of diagnostic biopsy.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Patients with surgically cured secondary malignancy who have been disease free &gt; 5
             years are eligible.

        Exclusion Criteria:

          -  Radiologic evidence of bone destruction.

          -  Previous or concurrent head and neck primaries.

          -  Prior surgery to study site other than biopsy.

          -  Patients receiving any other investigational agents.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study because treatments and agents have the
             potential for teratogenic or abortifacient effects. For this reason, women of
             child-bearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation. Should a woman become pregnant or suspect she is pregnant
             while participating in this study, she should inform her treating physician
             immediately.

          -  History of a prior or concomitant malignancy (other than carcinoma in situ of the
             cervix, basal cell or squamous cell carcinoma of the skin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krishna Rao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SIU School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Robbins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Institute at SIU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simmons Cooper Cancer Institute/SIU School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siumed.edu/cancer/</url>
    <description>official website of the SimmonsCooper Cancer Institute at SIU</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2006</study_first_submitted>
  <study_first_submitted_qc>March 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <results_first_submitted>November 2, 2016</results_first_submitted>
  <results_first_submitted_qc>June 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2017</results_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>RADPLAT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment open between May 2006 and October 2009 at a small academic center outpatient otolaryngology/ oncology clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RADPLAT and Tarceva</title>
          <description>All patients will receive RADPLAT and Tarceva:
Drug: Erlotinib (Tarceva)
150 mg daily X 7 weeks
Other Names:
Tarceva
Drug: Intra-arterial Cisplatin (PLAT)
1 dose (150 mg/sq) per week X 4 weeks
Other Names:
Cisplatin
Radiation: Radiation Therapy (RAD)
5 days per week X 7 weeks
Erlotinib (Tarceva): 150 mg daily X 7 weeks
Intra-arterial Cisplatin (PLAT): 1 dose (150 mg/sq) per week X 4 weeks
Radiation Therapy (RAD): 5 days per week X 7 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>lack of insurance coverage for chemoRT</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PT had medical condition preventing TX</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RADPLAT and Tarceva</title>
          <description>All patients will receive RADPLAT and Tarceva:
Drug: Erlotinib (Tarceva)
150 mg daily X 7 weeks
Other Names:
Tarceva
Drug: Intra-arterial Cisplatin (PLAT)
1 dose (150 mg/sq) per week X 4 weeks
Other Names:
Cisplatin
Radiation: Radiation Therapy (RAD)
5 days per week X 7 weeks
Erlotinib (Tarceva): 150 mg daily X 7 weeks
Intra-arterial Cisplatin (PLAT): 1 dose (150 mg/sq) per week X 4 weeks
Radiation Therapy (RAD): 5 days per week X 7 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T stage of Tumor at diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>T4 stage of tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T3 stage of tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>N stage of Tumor at diagnosis</title>
          <description>T3 Tumor &gt; 4cm in greatest dimension
T4a - Moderately advanced local disease
T4b - Very Advanced local disease
N0-no regional lymph node metastasis
N1-metastasis in a single ipsilateral lymph node 3cm or less in greatest dimension
N2-metastasis in a single ipsilateral lymph node &gt; 3cm but not more than 6cm in greatest dimension; or in multiple ipsilateral lymph nodes, none &gt; 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none&gt; 6 cm in greatest dimension
N3 Metastasis in a lymph node &gt; 6cm greatest dimension</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>N0 stage of tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>N1 stage of tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>N2 Stage of tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete and Partial Response Using RECIST Criteria</title>
        <description>Complete and Partial Response as defined by RECIST 1.0. Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD</description>
        <time_frame>17 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RADPLAT and Tarceva</title>
            <description>All patients will receive RADPLAT and Tarceva:
Drug: Erlotinib (Tarceva)
150 mg daily X 7 weeks
Other Names:
Tarceva
Drug: Intra-arterial Cisplatin (PLAT)
1 dose (150 mg/sq) per week X 4 weeks
Other Names:
Cisplatin
Radiation: Radiation Therapy (RAD)
5 days per week X 7 weeks
Erlotinib (Tarceva): 150 mg daily X 7 weeks
Intra-arterial Cisplatin (PLAT): 1 dose (150 mg/sq) per week X 4 weeks
Radiation Therapy (RAD): 5 days per week X 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete and Partial Response Using RECIST Criteria</title>
          <description>Complete and Partial Response as defined by RECIST 1.0. Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Post Treatment</title>
        <description>Overall Survival with a minimum follow up of 1year. Relapse/Persistent Disease Rates</description>
        <time_frame>22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RADPLAT and Tarceva</title>
            <description>All patients will receive RADPLAT and Tarceva:
Drug: Erlotinib (Tarceva)
150 mg daily X 7 weeks
Other Names:
Tarceva
Drug: Intra-arterial Cisplatin (PLAT)
1 dose (150 mg/sq) per week X 4 weeks
Other Names:
Cisplatin
Radiation: Radiation Therapy (RAD)
5 days per week X 7 weeks
Erlotinib (Tarceva): 150 mg daily X 7 weeks
Intra-arterial Cisplatin (PLAT): 1 dose (150 mg/sq) per week X 4 weeks
Radiation Therapy (RAD): 5 days per week X 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Post Treatment</title>
          <description>Overall Survival with a minimum follow up of 1year. Relapse/Persistent Disease Rates</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RADPLAT and Tarceva</title>
          <description>All patients will receive RADPLAT and Tarceva:
Drug: Erlotinib (Tarceva)
150 mg daily X 7 weeks
Other Names:
Tarceva
Drug: Intra-arterial Cisplatin (PLAT)
1 dose (150 mg/sq) per week X 4 weeks
Other Names:
Cisplatin
Radiation: Radiation Therapy (RAD)
5 days per week X 7 weeks
Erlotinib (Tarceva): 150 mg daily X 7 weeks
Intra-arterial Cisplatin (PLAT): 1 dose (150 mg/sq) per week X 4 weeks
Radiation Therapy (RAD): 5 days per week X 7 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>stridor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Krishna Rao</name_or_title>
      <organization>Southern Illinois University</organization>
      <phone>217-545-7969</phone>
      <email>krao@siumed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

